Canada - English - Health Canada

sivem pharmaceuticals ulc - metoprolol tartrate - tablet - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - metoprolol tartrate - tablet - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

Canada - English - Health Canada

pro doc limitee - metoprolol tartrate - tablet (extended-release) - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

Canada - English - Health Canada

qd pharmaceuticals ulc - metoprolol tartrate - tablet - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

Canada - English - Health Canada

pro doc limitee - metoprolol tartrate - tablet (extended-release) - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 95mg; metoprolol succinate 95mg; metoprolol succinate 95mg - modified release tablet - 95 mg - active: metoprolol succinate 95mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 95mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 95mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - metoprolol tartrate 100mg - tablet - 100 mg - active: metoprolol tartrate 100mg excipient: colloidal silicon dioxide hypromellose indigo carmine magnesium stearate microcrystalline cellulose povidone purified water shellac sodium starch glycolate titanium dioxide - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 95mg equivalent to metoprolol tartrate 100mg - modified release tablet - 95 mg - active: metoprolol succinate 95mg equivalent to metoprolol tartrate 100mg excipient: cellulose acetate crospovidone glyceryl monostearate hypromellose methacrylic acid copolymer microcrystalline cellulose opadry clear ys-1-7006 opadry white ys-1-7003 poloxamer 188 polysorbate 80 sugar spheres - metoprolol succinate extended-release tablets are indicated for the treatment of: hypertension - to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - metoprolol tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - metoprolol tartrate -